文献速递临床试验与 GCP

抗病毒漱口水对SARS-CoV-2唾液及鼻腔病毒载量影响的随机对照试验方案摘要

Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-11-02

本研究为多中心、随机、双盲、安慰剂对照试验,计划纳入206例新冠患者,比较含β-环糊精和Citrox®漱口水与安慰剂漱口水每日三次使用7天对唾液及鼻腔SARS-CoV-2病毒载量的影响。主要结局为唾液病毒载量从基线至第6天的变化,采用实时PCR检测。

要点

  • 含β-环糊精和Citrox®的漱口水可能降低唾液SARS-CoV-2病毒载量。
  • 试验采用双盲、随机、安慰剂对照设计,计划样本量206例。
  • 主要结局为唾液病毒载量动态变化,鼻腔病毒载量为次要结局。

核心结论

  • 该研究旨在评估含抗病毒成分漱口水对SARS-CoV-2唾液和鼻腔病毒载量的影响,目前方案已发布,结果尚未报告。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,1:1平行分组,计划纳入206例18-85岁新冠患者。
  • 纳入标准:临床诊断新冠、症状出现少于8天、病毒学确诊、签署知情同意。
  • 排除标准:妊娠或哺乳、无法遵守方案、定期使用漱口水(每周超过一次)、感染性心内膜炎风险等。
  • 随机化采用计算机生成的简单随机数字,参与者、医护人员、实验室技术人员和结果评估者均设盲。

关键数值与推荐

  • 干预组每日三次使用含β-环糊精和Citrox®的漱口水,持续7天;对照组使用安慰剂漱口水。
  • 主要结局:唾液SARS-CoV-2病毒载量从基线至4小时、9小时、1-6天的变化,实时PCR检测。
  • 次要结局:鼻腔SARS-CoV-2病毒载量从基线至第6天的变化,实时PCR检测。
  • 样本量:干预组和对照组各103例,共206例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: - To describe the evolution of the SARS-CoV-2 salivary viral load of patients infected with Covid-19, performing 7 days of tri-daily mouthwashes with and without antivirals. - To compare the evolution of the SARS-CoV-2 nasal and salivary viral load according to the presence or absence of antivirals in the mouthwash. TRIAL DESIGN: This is a multi-center, randomised controlled trial (RCT) with two parallel arms (1:1 ratio). PARTICIPANTS: Inclusion criteria - Age: 18-85 years old - Clinical diagnosis of Covid-19 infection - Clinical signs have been present for less than 8 days - Virological confirmation - Understanding and acceptance of the trial - Written agreement to participate in the trial Exclusion criteria - Pregnancy, breastfeeding, inability to comply with protocol, lack of written agreement - Patients using mouthwash on a regular basis (more than once a week) - Patient at risk of infectious endocarditis - Patients unable to answer questions - Uncooperative patient The clinical trial is being conducted with the collaboration of three French hospital centers: Hospital Center Emile Roux (Le Puy en Velay, France), Clinic of the Protestant Infirmary (Lyon, France) and Intercommunal Hospital Center (Mont de Marsan, France). INTERVENTION AND COMPARATOR: Eligible participants will be allocated to one of the two study groups. Intervention group: patients perform a tri-daily mouthwash with mouthwash containing antivirals (β-cyclodextrin and Citrox®) for a period of 7 days. CONTROL GROUP: patients perform a tri-daily mouthwash with a placebo mouthwash for a period of 7 days. MAIN OUTCOMES: Primary Outcome Measures: Change from Baseline amount of SARS-CoV-2 in salivary samples at 4 and 9 hours, 1, 2, 3, 4, 5 and 6 days. Real-time PCR assays are performed to assess salivary SARS-CoV 2 viral load. SECONDARY OUTCOME MEASURES: Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 6 days. Real-time PCR assays are performed to assess nasal SARS-CoV-2 viral load. RANDOMISATION: Participants meeting all eligibility requirements are allocated to one of the two study arms (mouthwash with β-cyclodextrin and Citrox® or mouthwash without β-cyclodextrin and Citrox®) in a 1:1 ratio using simple randomisation with computer generated random numbers. BLINDING (MASKING): Participants, doctors and nurses caring for participants, laboratory technicians and investigators assessing the outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Both the intervention and control groups will be composed of 103 participants, so the study will include a total of 206 participants. TRIAL STATUS: The current protocol version is 6, August 4th, 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021. As of October 2, 2020, forty-two participants have been included. TRIAL REGISTRATION: This trial was registered on 20 April 2020 at www.clinicaltrials.gov with the number NCT04352959 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2)."

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Carrouel F, Viennot S, Valette M, et al. Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33138848. doi:10.1186/s13063-020-04846-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。